Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

• ClinicalTrials.gov Identifier: NCT01821963
• Recruitment Status: Terminated
• First Posted: April 1, 2013
• Results First Posted: March 6, 2015
• Last Update Posted: September 24, 2020
• Sponsor: M.D. Anderson Cancer Center
• Collaborator: Vertex Pharmaceuticals Incorporated
• Information provided by (Responsible Party): M.D. Anderson Cancer Center

Study Description

Brief Summary:

The goal of this clinical research study is to learn if the antiviral combination of telaprevir, pegylated Interferon Alfa 2a (PegIFN alfa-2a) and ribavirin (RBV) can prevent the virus from coming back after the liver transplant.

Telaprevir, PegIFN alfa-2a, and RBV are different antiviral drugs that work in combination at different stages of the HCV infection to stop the virus.

Condition or disease	Intervention/treatment	Phase
Infection	Drug: Pegylated Interferon Alfa 2a; Drug: Ribavirin; Drug: Telaprevir	Phase 3

Detailed Description:

Study Drug Administration:

If you are found to be eligible to take part in this study, you will take telaprevir 3 times a day. You will take RVB by mouth 2 times a day. You will receive PEGIFN alfa-2a by an injection under the skin 1 time a week.

Study Visits:

On the first day you take the study drug:

• You will have an eye exam performed by the study doctor.
• You will have a physical exam, including measurement of your vital signs (blood pressure, heart rate, temperature, and breathing rate).
• Blood (about 2 teaspoons) will be drawn for routine tests and to check for the hepatitis virus.
• You will be asked about any drugs you are taking or side effects you may be having.

Every Week while you are on study:

• You will have a physical exam, including measurement of your vital signs.
• Blood (about 2 teaspoons) will be drawn for routine tests and to check for the hepatitis C virus. If part of the blood sample is left over after the Hepatitis C testing, it will be stored in the laboratory as a back-up sample, in case the original samples get lost. This sample may also be used to check if the Hepatitis C virus has become resistant to the study drug. No extra blood will be drawn for this storage.
• You will be asked about any drugs you are taking or side effects you may be having.
• At Weeks 12, 24, 36, and 42, urine will be collected to check for infection and any other side effects to the drugs.

If you can become pregnant, you will have a urine pregnancy test every 4 weeks

Length of Treatment:

You may continue receiving the antiviral therapy for up to 48 weeks, as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your participation on the study will be over after the follow-up visits.

Follow-Up Visits:

Beginning the day after you stop taking antiviral therapy (or the day of transplantation, whichever comes first), you will have up to 24 weeks of follow-up testing performed. About 4 and 20 weeks after your last dose:

• You will have a physical exam, including measurement of your vital signs.
• Blood (about 2 teaspoons) will be drawn for routine tests and to check for the hepatitis C virus.
• You will be asked about any side effects you may be having.
• At week 4 only, urine will be collected to check for infection and any other side effects to the drugs.

This is an investigational study. Telaprevir, PegIFN alfa-2a, and RBV are all FDA approved and commercially available for the treatment of HCV infection. The use of these drugs in preventing the HCV infection is investigational.

Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation
• Study Start Date: April 2013
• Actual Primary Completion Date: February 2014
• Actual Study Completion Date: February 2014

Arms and Interventions

Arm

Intervention/treatment

Experimental: Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir; Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.

Drug: Pegylated Interferon Alfa 2a; Starting dose: 180 mcg subcutaneously once weekly.; Other Name: PegIFN; Drug: Ribavirin; Starting dose: 1,000 mg by mouth daily.; Drug: Telaprevir; Starting dose: 750 mg by mouth 3 times a day.; Other Name: Incivek

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant [ Time Frame: 12 weeks post-transplant, up to 48 weeks for overall monitoring ]

   The primary endpoint is number of participants with undetectable viral load at 12 weeks post-transplant (Post-transplant virological response, (PTVR)) which is defined as undetectable Hepatitis C Virus ribonucleic acid (HCV-RNA) 12 weeks after liver transplantation). In order to have undetectable HCV RNA viral load after transplant, participants need to have undetectable viral load before the liver transplant.

   Response rate based on the modified intent-to-treat (ITT) population where ITT population is defined as those patients who have achieved an undetectable HCV-RNA level before the transplant. If patients drop out the study early due to severe toxicity or treatment failure including treatment-related death, they will be counted as non-responders when evaluating the response rate.

Secondary Outcome Measures :

1. Sustained Virological Response (SVR) [ Time Frame: 60 weeks ]
   Sustained virological response (SVR) defined as a single undetectable HCV-RNA measurement 12 weeks after the 48-week treatment period for those still waiting for transplantation. The treatment duration will be summarized with descriptive statistics. Additional analyses based on evaluable patients also conducted regarding the PTVR response rate. The evaluable patients are defined as those patients who complete at least 16 weeks of treatment and have the 12 weeks post-transplant response measurement. The rate will also be computed stratified by the HCV treatment time (i.e., the 48-week HCV treatment versus less than 48 week HCV treatment) considering the different times under HCV. The SVR rate will be estimated, along with the exact 95% confident interval.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 69 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Males or females aged ≥ 18 and ≤ 70 years
2. Detectable Hepatitis C Virus ribonucleic acid (HCV-RNA) in serum
3. HCV genotype 1 infection
4. Child-Pugh-Turcotte (CPT) score < 7 and Model for End-Stage Liver Disease (MELD) score < 18
5. PegIFN alfa-2a/RBV-naïve or previously treated patients (partial responders, null responders and relapsers)

6. Hepatocellular carcinoma within transplant criteria in the United Network for Organ Sharing (UNOS) Region IV:

   1. Single lesion up to 6 cm, or
   2. Two or three lesions with largest no greater than 5 cm and the total tumor diameter no greater than 9 cm
7. Listed for liver transplantation
8. Willingness to give written consent and agree to double contraception

Exclusion Criteria:

1. Decompensated cirrhosis
2. Baseline platelet count less than 35,000/µL
3. Baseline hemoglobin level less than 10 g/dL
4. Baseline absolute neutrophil count less than 750/mm3
5. Baseline creatinine clearance < 50 mL per min.
6. Women with a positive pregnancy test at baseline or men whose female partners are pregnant or are contemplating pregnancy
7. Intolerance or contraindications to PegIFN alfa-2a/RBV use per standard treatment guidelines

Contacts and Locations

Locations

United States, Texas

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Vertex Pharmaceuticals Incorporated

Investigators

• Principal Investigator: Harrys A. Torres, MD; M.D. Anderson Cancer Center

More Information

Additional Information:

University of Texas MD Anderson Cancer Center Website 

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT01821963
• Other Study ID Numbers: 2012-0977
• First Posted: April 1, 2013
• Results First Posted: March 6, 2015
• Last Update Posted: September 24, 2020
• Last Verified: September 2020

Keywords provided by M.D. Anderson Cancer Center:

Infection; Hepatitis C Genotype 1 Infection; Hepatitis C virus; HCV; Hepatocellular Carcinoma; HCC; Liver Transplantation; Pegylated Interferon Alfa 2a; PegIFN alfa-2a; Ribavirin; RBV; Telaprevir; Incivek; Antiviral drugs

Additional relevant MeSH terms:

Infections; Communicable Diseases; Carcinoma; Carcinoma, Hepatocellular; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Disease Attributes; Pathologic Processes; Liver Diseases; Digestive System Diseases; Adenocarcinoma; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Interferons; Ribavirin; Interferon-alpha; Interferon alpha-2; Peginterferon alfa-2a; Antineoplastic Agents; Antiviral Agents; Anti-Infective Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Immunologic Factors; Physiological Effects of Drugs